HUTCHMED (China) HMDCF
NASDAQ HMDCF
$2.16 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

HUTCHMED (China) (HMDCF) Total Non-Current Liabilities (2015 - 2026)

HUTCHMED (China)'s (HMDCF) quarterly Total Non-Current Liabilities came in at $363.6 million in Q2 2026, up 6072.78% year-over-year from $5.9 million in Q2 2025, and up 7222.8% quarter-over-quarter from $5.0 million in Q4 2025.

Analysis

HUTCHMED (China) (HMDCF) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends

HUTCHMED (China) (HMDCF) has reported Total Non-Current Liabilities for 12 consecutive years, with $363.6 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Total Non-Current Liabilities rose 6072.78% year-over-year to $363.6 million in Q2 2026; TTM through Jun 2026 was $363.6 million, a 6072.78% increase from a year earlier, with the FY2025 full-year figure at $5.0 million, up 28.69% from the prior year.
  • Total Non-Current Liabilities was $363.6 million for Q2 2026 at HUTCHMED (China), up from $5.0 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $478.2 million in Q2 2023 and troughed at $3.7 million in Q4 2023.
  • A 5-year average of $97.2 million and a median of $5.0 million in 2025 frame the typical range for Total Non-Current Liabilities.
  • Across the five-year window, Total Non-Current Liabilities jumped 7835.38% in 2023 and plunged 99.16% in 2024, its largest moves.
  • Over 5 years, Total Non-Current Liabilities stood at $4.9 million in 2022, then slipped by 25.42% to $3.7 million in 2023, then grew by 4.64% to $3.9 million in 2024, then increased by 28.69% to $5.0 million in 2025, then surged by 7222.8% to $363.6 million in 2026.
  • The last three Total Non-Current Liabilities figures came in at $363.6 million (Q2 2026), $5.0 million (Q4 2025), and $5.9 million (Q2 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Amgen 211.51 Bn 197.52 Bn 7.24 Bn 81.11 Bn
2 Gilead Sciences 181.48 Bn 178.30 Bn 6.22 Bn 36.04 Bn
3 Vertex Pharmaceuticals 132.45 Bn 124.60 Bn 2.84 Bn 5.92 Bn
4 Regeneron Pharmaceuticals 82.87 Bn 74.88 Bn 3.93 Bn 7.74 Bn
5 Argenx Se 61.59 Bn 56.41 Bn 1.37 Bn 40.00 Mn
6 Moderna 54.72 Bn 49.59 Bn 52.00 Mn 3.92 Bn
7 Alnylam Pharmaceuticals 34.13 Bn 30.82 Bn 992.69 Mn 4.20 Bn
8 Biogen 31.29 Bn 30.01 Bn 1.96 Bn 12.42 Bn
9 Roivant Sciences 30.31 Bn 30.31 Bn 1.16 Mn 378.37 Mn
10 HUTCHMED (China) 376.85 Mn 391.04 Mn - 363.58 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 363.58 Mn
Dec 31, 2025 4.97 Mn
Jun 30, 2025 5.89 Mn
Dec 31, 2024 3.86 Mn
Jun 30, 2024 4.03 Mn
Dec 31, 2023 3.69 Mn
Jun 30, 2023 478.19 Mn
Dec 31, 2022 4.94 Mn
Jun 30, 2022 6.03 Mn
Dec 31, 2021 7.13 Mn
Jun 30, 2021 28.67 Mn
Mar 31, 2021 221.92 Mn
Dec 31, 2020 16.03 Mn
Jun 30, 2020 -37.62 Mn
Dec 31, 2019 -48.69 Mn
Sep 30, 2019 108.85 Mn
Jun 30, 2019 114.32 Mn
Mar 31, 2019 130.61 Mn
Dec 31, 2018 17.30 Mn
Jun 30, 2018 117.25 Mn